Project
MS201924_0002
Ongoing - recruitment active · 2024 until 2028
Huober Jens, Dei Cas Alissa, Müller Fiona
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment active
Start Date
2024
End Date
2028
Financing
Industry
Labels
gynecological tumors
Brief description/objective
An open-label, multicenter, randomized Phase 2 study of the ATR inhibitor tuvusertib in combination with the PARP inhibitor niraparib or the ATM inhibitor lartesertib in participants with BRCA mutant and/or homologous recombination deficiency (HRD) positive epithelial ovarian cancer that progressed on prior PARP inhibitor therapy